Mereo BioPharma (MREO) EBT Margin (2023 - 2025)

Mereo BioPharma (MREO) posted quarterly EBT Margin of 2923.2% for Q2 2025, down 203.21% on a QoQ basis from 964.1% in Q4 2023.

Mereo BioPharma (MREO) EBT Margin (2023 - 2025) Analysis & Trends

Mereo BioPharma (MREO) has reported EBT Margin for 2 consecutive years, with 2923.2% the latest figure, recorded in Q2 2025.

Quarterly EBT Margin changed N/A year-over-year to 2923.2% in Q2 2025, while the trailing twelve-month figure through Dec 2025 was 8375.6% (changed N/A YoY) and the FY2025 annual result came in at 8375.6%, changed N/A from the prior year.
EBT Margin eased to 2923.2% in Q2 2025 per MREO's latest filing, from 964.1% in the prior quarter.
Over the last five years, EBT Margin for MREO reached as high as 19.46% in Q2 2023 and fell as low as 2923.2% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	17.13%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	41.95%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.05%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	34.77%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Mereo BioPharma	232.52 Mn	232.52 Mn	-	-

Download Data